Inhibrx Biosciences, Inc. (INBX) Dividend History

Company News

• Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com

  JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.

  Investing.com
• Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates

  Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: VCEL
• BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates

  BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: BMRN
• Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX

  J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.

  Zacks Investment Research

  Featured Companies: IONS JNJ
• Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More

  Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.

  Zacks Investment Research

  Featured Companies: EXEL GILD